SCHEMBL3268951

SCHEMBL3268951

O=C(Nc1ccccc1)N1CCN(c2cccc(-c3ccc(F)cc3F)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.63
HTT P42858 2/20 0.59
LMNA P02545 1/20 0.59
POLB P06746 4/20 0.59
MAPT P10636 3/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HCRTR1 O43613 1/20 0.59
USP2 O75604 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
MAPK1 P28482 1/20 0.59
CYP2C19 P33261 1/20 0.59
FAAH O00519 5/20 0.54
NAMPT P43490 1/20 0.53
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA9 Q16790 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269596 0.88 FAAH (0.61) GLAHTTLMNAPOLBMAPT
SCHEMBL3269282 0.86 POLB (0.60) GLAHTTLMNAPOLBMAPT
SCHEMBL3272217 0.82 FAAH (0.80) MAPTFAAHTP53
SCHEMBL3272253 0.81 FAAH (0.62) POLBMAPTFAAHTP53MAPK10
SCHEMBL3268551 0.81 FAAH (0.53) GLAPOLBMAPTFAAHTP53
SCHEMBL3272478 0.80 FAAH (0.50) GLAPOLBMAPTFAAHCA12
SCHEMBL3269233 0.80 FAAH (0.49) POLBMAPTFAAHCA12CA1
SCHEMBL3269790 0.79 FAAH (0.71) GLAHTTLMNAPOLBMAPT
SCHEMBL3268311 0.78 FAAH (0.74) GLAPOLBMAPTFAAHNAMPT
Hydrochloric Acid SCHEMBL3272648 0.77 FAAH (0.73) GLAPOLBMAPTFAAHNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA GLA 2959/4885HTT 3560/4885LMNA 4792/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA GLA 2959/4885HTT 3560/4885LMNA 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.